Analysts expect Vericel Co. (NASDAQ:VCEL) to announce sales of $36.92 million for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Vericel’s earnings. The lowest sales estimate is $35.10 million and the highest is $38.64 million. Vericel reported sales of $20.01 million during the same quarter last year, which indicates a positive year-over-year growth rate of 84.5%. The firm is scheduled to issue its next earnings results on Wednesday, August 4th.
According to Zacks, analysts expect that Vericel will report full year sales of $166.89 million for the current fiscal year, with estimates ranging from $166.20 million to $167.53 million. For the next financial year, analysts forecast that the business will post sales of $216.08 million, with estimates ranging from $208.75 million to $235.25 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover Vericel.
Vericel (NASDAQ:VCEL) last announced its quarterly earnings data on Tuesday, May 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.03). Vericel had a net margin of 3.24% and a return on equity of 3.45%. The business had revenue of $34.57 million during the quarter, compared to analyst estimates of $32.04 million. During the same quarter last year, the firm posted ($0.10) EPS. The company’s revenue for the quarter was up 29.6% on a year-over-year basis.
Vericel stock traded up $0.01 during trading on Tuesday, reaching $57.67. The stock had a trading volume of 2,508 shares, compared to its average volume of 755,126. Vericel has a 52-week low of $12.82 and a 52-week high of $64.89. The firm has a 50 day moving average of $55.87. The stock has a market capitalization of $2.67 billion, a PE ratio of 720.84 and a beta of 2.10.
In related news, Director Paul K. Wotton sold 13,448 shares of the company’s stock in a transaction on Tuesday, May 11th. The shares were sold at an average price of $50.11, for a total value of $673,879.28. Following the completion of the sale, the director now owns 21,000 shares in the company, valued at approximately $1,052,310. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Paul K. Wotton sold 5,000 shares of the company’s stock in a transaction on Friday, May 14th. The shares were sold at an average price of $50.52, for a total transaction of $252,600.00. Following the completion of the sale, the director now owns 26,602 shares of the company’s stock, valued at approximately $1,343,933.04. The disclosure for this sale can be found here. In the last quarter, insiders sold 116,372 shares of company stock valued at $6,208,573. 4.60% of the stock is owned by insiders.
A number of hedge funds have recently added to or reduced their stakes in the stock. Cambridge Investment Research Advisors Inc. raised its position in Vericel by 2.0% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 21,428 shares of the biotechnology company’s stock valued at $1,190,000 after purchasing an additional 415 shares during the last quarter. Sowell Financial Services LLC acquired a new position in Vericel in the 1st quarter valued at $29,000. The Manufacturers Life Insurance Company increased its stake in Vericel by 2.3% in the 4th quarter. The Manufacturers Life Insurance Company now owns 26,977 shares of the biotechnology company’s stock valued at $833,000 after buying an additional 612 shares during the period. Captrust Financial Advisors acquired a new position in Vericel in the 1st quarter valued at $36,000. Finally, UBS Asset Management Americas Inc. increased its stake in Vericel by 3.9% in the 1st quarter. UBS Asset Management Americas Inc. now owns 30,617 shares of the biotechnology company’s stock valued at $1,701,000 after buying an additional 1,138 shares during the period.
Vericel Company Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns.
Read More: Short Selling
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.